![]() ![]() Too many Patients suffer or have been lost due to cancer. What we do not need are price control policies such as those in the Build Back Better Act which threaten future innovation and disincentivize further research into cancer. To achieve this important goal, we need policies that support and promote medical innovation to stimulate future oncology cures and treatments. ![]() Meanwhile, BioNJ applauds President Biden on reigniting his “ Cancer Moonshot ” effort, with the goal of reducing cancer deaths by 50% over the next 25 years and improving the experience for those living with and surviving the disease. Click here for BioNJ’s whitepaper which demystifies some of the myths commonly used in support of Prescription Drug Affordability Board proposals. ![]() ![]() Rather than taking a systemwide, holistic approach that addresses the drug supply chain middlemen, coinsurance, co-payments and health benefit design issues that can have the biggest impact on Patient costs, PDAB proposals focus squarely on the innovative biopharmaceutical sector without any guarantee of Patient savings on necessary and lifesaving prescription treatments. BioNJ President and CEO Debbie Hart was on hand to testify with a message that a Prescription Drug Affordability Board is the wrong way to lower Patient out-of-pocket costs. Yesterday, A-1747/S-329, legislation to create a Prescription Drug Affordability Board, was heard and released by the Assembly Financial Institutions and Insurance Committee. Things are getting busy once again in both Trenton and Washington. Welcome to t he l atest edition of the BioLines Weekender. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |